Supernus Q3 revenue $177.4M (+19% YoY); guides FY2022 revenue $650-680M

SUPERNUS PHARMACEUTICALS, INC.

2022-Q3 EPS reported $0.62 revenue$499,910,000

GAAP net earnings $1.7M ($0.03 diluted EPS); adjusted op earnings $25.4M vs $43.3M prior year.
Total revenues $177.4M (+19% YoY); Qelbree sales $18.3M (+65% QoQ) with 94,328 prescriptions.
FY 2022 guidance raised: total revenue $650-680M (from $640-680M) and GAAP op earnings $35-45M (from $20-40M).
FDA issued CRL for SPN-830 (apomorphine device; Parkinson's); no new efficacy/safety trials needed but device and quality info required; Class 2 review timeline (6 months).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SUPERNUS PHARMACEUTICALS, INC. updated its third quarter ended September 30, 2022 guidance (raised).

Period: third quarter ended September 30, 2022
Guidance: raised
Result: reported results

Exact text from the filing

Supernus Announces Third Quarter 2022 Financial Results • Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021 • Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million to $40 million previously • Increasing full year 2022 total revenues guidance to $650 million to $680 million, from $640 million to $680 million previously

View on SEC.gov

Browse all earnings releases →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-22-000071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.